Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

News Conference News AHA 2020

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

November 18, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

News Conference News AHA 2020

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

November 13, 2020

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

November 16, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

Remission, Not Cure: No Weaning Off Meds for Dilated Cardiomyopathy Patients, Says TRED-HF

News Conference News AHA 2018

Remission, Not Cure: No Weaning Off Meds for Dilated Cardiomyopathy Patients, Says TRED-HF

November 11, 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

Methamphetamine Use Growing More Common in Veterans With Heart Failure

News Conference News AHA 2017

Methamphetamine Use Growing More Common in Veterans With Heart Failure

November 24, 2017

More Support for TMVR After Failed Mitral Bioprostheses

News Conference News AHA 2017

More Support for TMVR After Failed Mitral Bioprostheses

Yael L. Maxwell

November 23, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.